(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces its financial results for its fiscal quarter ended April 30, 2017. Helix-BioPharma-Corp.-Announces-Fiscal-Third-Quarter-2017-Results-June-13-2017.pdf
(Toronto, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for gross proceeds of approximately CAD3,028,800. Helix-BioPharma-Corp.-Closes-Private-Placement-June-7-2017.pdf
(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that company Chief Executive Officer and Chief Science Officer, Heman Chao, will be presenting at the upcoming 3rd Annual Immuno-oncology BD&L […]
(Toronto, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for aggregate gross proceeds of approximately CAD820,000. Helix-BioPharma-Corp.-Closes-Private-Placement-April-27-2017.pdf
(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that its poster entitled: CART cell harboring a camelid single domain antibody as a targeting agent to kill tumours expressing VEGFR2 […]
(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that results from the Phase I L-DOS47 study will be presented at the upcoming 9th International Conference of Contemporary Oncology meeting in Poznan, Poland from the 22nd to […]
(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces its financial results for its fiscal quarter ended January 31, 2017. 20170321-Helix-PR.pdf